Switching tristetraprolin on to turn off inflammation in COPD

炎症驱动慢性阻塞性肺疾病（COPD）的发病机制。我们已经开发出一种新的抗炎策略来治疗这种目前无法治愈的疾病。我们的创新是使用蛋白磷酸酶2A的激活剂来开启三戊三醇分子（TTP）并抑制慢性阻塞性肺病的炎症。打开TTP以关闭COPD中的炎症已被证明有可能预防不可逆的损害并阻止COPD的进展。

Inflammation drives the pathogenesis of chronic obstructive pulmonary disease (COPD). We have developed a novel anti-inflammatory strategy to treat this currently untreatable disease. Our innovation is to use activators of protein phosphatase 2A to switch the molecule tristetraprolin (TTP) on and repress inflammation in COPD. Switching TTP on to turn off inflammation in COPD has proven potential to prevent irreversible damage and halt the progression of COPD.